valu usd unless otherwis note
view momentum gener surgeri continu allow
continu spend acceler develop work pipelin
technolog expand allow compani remain
premium player surgic robot market rais
estim pt move higher
post better expect result report
non-gaap revenu fce y/i upsid
driven better system instruments/accessori revenu
non-gaap ep fce non-gaap oper margin
fce y/i partli due time
market engin ou clinic data expens
weight toward non-gaap fce
placement out-performance driven partli higher trade-
in oper leas world-wide system placement
fce system placement fce
intern system placement fce system ship
oper leas vs last quarter rbce trade-in
repres system placement vs
averag system price lower
estim due higher mix trade-in system
ship xi vs
da vinci system vs
rais procedur growth guidanc
fce appear reason potenti upsid
strong execut ww da vinci procedur grew impress
y/i fce da vinci procedur grew y/
rbce ou procedur grew y/i rbce
y/i urolog gynecolog gener surgeri growth
acceler slightli estim gener surgeri
procedur grow y/i led solid growth hernia repair
colorect grow contribut bariatr thorac hpv
foregut instrument accessori revenue/procedur
rbce y/i
continu believ earli steep part
robot gener surgeri adopt curv surgic
robot launch slip month manag origin
expect believ clear runway next
month reinvest lot recent upsid advanc
new system/instru technolog market develop work
expand robot penetr intern market new
technolog front roll sureform surgic stapler
expect first custom shipment da vinci sp occur late
manag also continu expect fda
file flexibl cathet system year-end
price prior trade day market close estimate unless otherwis note
bloomberg capit market estim upside/downside/target
base scenario assum share price target
base weight intrins
valu calcul dcf analysi
weight intrins valu calcul
ev/ebitda analysi assum
continu increas penetr us gener surgeri
intern surgic market estim
world-wide instal base system
da vinci procedur perform annual includ
upsid scenario assum share rise
base dcf model termin valu
ev/ebitda multipl assum continu
increas penetr us gener surgeri
intern surgic market addit assum
acceler upgrad opportun da vinci
success penetr natur orific procedur sp
dollar lung biopsi opportun jv
fosun pharma estim world-wide
instal base system da vinci procedur
perform annual includ lung biopsi
downsid scenario assum share fall
base dcf model termin valu ev/ebitda
multipl also assum ultim penetr
gener surgeri market disappoint da vinci sp
competit robot entri us forc
addit pressur da vinci price estim
world-wide instal base nearli system
da vinci procedur perform annual
includ lung biopsi assum lung biopsi
platform delay
believ share perform line
peer group follow key reason
 da vinci prostatectomi hysterectomi procedur
combin grow
penetr target us
prostatectomi us hysterectomi market robot
respect two procedur compris
total procedur believ issu lead
past slow market well behind
expect market-lik growth dvp
take
gener surgeri market repres main near-
term procedur growth driver recent strong
colorectal/hernia trend appear sustain
urolog gynecolog market combin
time train surgeon
develop opportun isrg gener surgeri
procedur growth focus cholecystectomi
us
howev cholecystectomi flattish four
main growth driver gener surgeri hernia
colorect bariatr thorac recent channel
check robot survey give us confid
real sustain opportun
pictur continu execut growth
strategi gener surgeri intern
pipelin expand remain confid two
import procedur growth driver
colorect hernia sustain
long runway ahead intern market system
front receiv fda approv da vinci sp
urolog procedur follow approv
transor colorect addit
earli human clinic experi prototyp flexibl
catheter-bas robot platform initi use
lung biopsi expect file flexibl
cathet platform year-end add yet anoth
outer-year growth opportun addit
analytics/imag opportun next-gener
system develop
upcom catalyst event
commerci da vinci sp commerci
lung biopsi system
commerci risk fda regulatori risk
competit risk legal risk reimburs risk
perform dcf ev/ebitda analysi arriv intrins valu
share dcf analysi use wacc assum termin valu ev/ebitda
multipl base dcf analysi estim intrins valu
approxim separ conduct ev/ebitda analysi use publicli
trade med-tech compar compani analysi point averag forward ev/
ebitda multipl large-cap med-tech compani super premium large-cap
med-tech diagnost compani assign target non-gaap ebitda
multipl premium peer group owe expect
superior top-lin growth rel peer given isrg above-averag oper
margin multipl equat intrins valu deriv price target
assign weight intrins valu calcul dcf analysi
weight intrins valu calcul ev/ebitda analysi
price target impli return support sector perform rate
risk rate price target
face risk typic medic devic compani risk price target
rate includ slower-than-expect gener surgeri procedur growth one
lead indic futur system placement slower-than-expect system ramp da
vinci xi sp lung biopsi procedur declin two three core
market hysterectomi prostatectomi competit risk titan
medic expect gain fda/eu approv robot system
time frame potenti neg public futur clinic studi surgic societi
advers event on-going lawsuit fda regulatori risk surround new robot
platform devic reimburs risk risk
found current market leader world-wide robot market
compani went public receiv fda approv two key indic
benign prostatectomi hysterectomi focus five key surgic
specialti urolog surgeri gynecolog surgeri gener surgeri cardiothorac surgeri
head neck surgeri urolog gynecolog procedur repres around two-
third total world-wide procedur perform da vinci system incorpor
delawar corpor headquart locat sunnyval california compani
manufactur da vinci system facil sunnyval california instrument
made sunnyval facil mexicali mexico facil
amort intang
